Guided Therapeutics (GTHP) Net Equity Issued and Repurchased (2017 - 2025)

Guided Therapeutics has reported Net Equity Issued and Repurchased for 6 years, with the latest figure at $535000.0 in Q4 2024.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $535000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.9 million (up 38.43% YoY) and the FY2025 annual result came in at $567000.0, down 32.1% from the prior year.
• Net Equity Issued and Repurchased advanced to $535000.0 in Q4 2024 per GTHP's latest filing, from -$4000.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $1.4 million in Q3 2022 and troughed at -$125000.0 in Q4 2021.
• A 4-year average of $275285.7 and a median of $103000.0 in 2020 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2021 and 2022: Net Equity Issued and Repurchased advanced 21.36% in 2021, then soared 96.8% in 2022.
• Over 4 years, Net Equity Issued and Repurchased stood at -$103000.0 in 2020, then slipped by 21.36% to -$125000.0 in 2021, then jumped by 96.8% to -$4000.0 in 2022, then jumped by 13475.0% to $535000.0 in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $535000.0, -$4000.0, and $1.4 million for Q4 2024, Q4 2022, and Q3 2022 respectively.